Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Faecalibaterium prausnitzii strain EXL01 boosts efficacy of Immune Checkpoint Inhibitors

ABSTRACT: Faecalibaterium prausnitzii strain EXL01 boosts efficacy of Immune Checkpoint Inhibitors

PROVIDER: PRJNA983285 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24911638_1.fastq.gz	Fastqsanger.gz
	SRR24911638_2.fastq.gz	Fastqsanger.gz
	SRR24911639_1.fastq.gz	Fastqsanger.gz
	SRR24911639_2.fastq.gz	Fastqsanger.gz
	SRR24911640_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 84

Similar Datasets

Faecalibaterium prausnitzii strain EXL01 boosts efficacy of Immune Checkpoint Inhibitors

Project description:Gut microbiota impacts responses to immune checkpoint inhibitors (ICI). High level of Faecalibacterium prausnitzii has been associated with a positive response to ICI in multiple cancer types. Here, we show in two independent cohorts of patients with non-small cell lung cancer and advanced melanoma that high level of F. prausnitzii at baseline is positively associated with a better clinical response to ICI. In a mouse preclinical model, we show that the F. prausnitzii strain EXL01, already in clinical development for Inflammatory Bowel Disease, restores the anti-tumor response to ICI in the context of antibiotic-induced microbiota perturbation at clinical and tumor transcriptomics level. In vitro, EXL01 strain enhances T cell activation in the presence of ICI. Interestingly, oral administration of EXL01 strain is not associated with a change in fecal microbiota diversity or composition suggesting a direct effect on immune cells in the small intestine.

2024-07-10 | GSE234818 | GEO

Faecalibacterium prausnitzii abrogates immunotherapy toxicity

Project description:To elucidate whether Faecalibacterium prausnitzii has effects on intestinal toxicity induced by immune checkpoint inhibitors, we performed RNA-seq analysis of colon tissues of mice receiving DSS, DSS+ICB and DSS+ICB+F. prausnitzii gavage to compare the gene expression profiles.

2023-08-11 | GSE224881 | GEO

Project description:Faecalibaterium prausnitzii strain EXL01 boosts immune checkpoint inhibitors effects

| PRJNA975093 | ENA

A microbiome-produced metabolite drives immunostimulatory macrophages and boosts response to immune checkpoint inhibitors in pancreatic cancer

Project description:A microbiome-produced metabolite drives immunostimulatory macrophages and boosts response to immune checkpoint inhibitors in pancreatic cancer

| PRJNA857724 | ENA

Colitis associated with immune checkpoint inhibitors

Project description:Colitis associated with immune checkpoint inhibitors

| PRJNA849977 | ENA

Transcriptomic studies on ruxolitinib with or without checkpoint inhibitors as a cancer therapy

Project description:Unleashing anti-tumor T cell activity by checkpoint inhibition is effective in many cancer patients but clinical response rates remain limited. Myeloid derived suppressor cells erode antitumor lymphocyte numbers and function, and correlate with resistance to checkpoint inhibitors. By screening small molecule libraries, we identified JAK inhibitors’ ability to rescue T cell function. Despite its documented immune suppressive properties, the prototypical JAK inhibitor ruxolitinib enhanced the efficacy of immune checkpoint blockade in cancer. This effect correlated with loss of suppressive gene expression, and acquisition of immunostimulatory molecular markers and T cell stimulatory activity in myeloid cells. In preclinical models, ruxolitinib significantly improved the function and increased the total numbers of activated tumor-infiltrating NK and CD4 T cells compared to checkpoint blockade alone and the efficacy was conditional on granulocytic cells. In addition to myeloid reprogramming in the tumor, ruxolitinib blunts G-CSF signaling in the bone marrow to prevent expression of suppressive and chemotaxis genes in neutrophils.

2024-06-20 | GSE209647 | GEO

A microbiome-produced metabolite drives immunostimulatory macrophages and boosts response to immune checkpoint inhibitors in pancreatic cancer [scRNA-seq]

Project description:A microbiome-produced metabolite drives immunostimulatory macrophages and boosts response to immune checkpoint inhibitors in pancreatic cancer [scRNA-seq]

| PRJNA857729 | ENA

A microbiome-produced metabolite drives immunostimulatory macrophages and boosts response to immune checkpoint inhibitors in pancreatic cancer [RNA-seq]

Project description:A microbiome-produced metabolite drives immunostimulatory macrophages and boosts response to immune checkpoint inhibitors in pancreatic cancer [RNA-seq]

| PRJNA857660 | ENA

Colitis associated with immune checkpoint inhibitors [tissue_cells]

Project description:Colitis associated with immune checkpoint inhibitors [tissue_cells]

| PRJNA849981 | ENA

Colitis associated with immune checkpoint inhibitors [tissue_nuclei]

Project description:Colitis associated with immune checkpoint inhibitors [tissue_nuclei]

| PRJNA849980 | ENA